Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;75(9):1269–1278. doi: 10.1038/bjc.1997.216

MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.

P Korkolopoulou 1, P Christodoulou 1, K Kouzelis 1, M Hadjiyannakis 1, A Priftis 1, G Stamoulis 1, A Seretis 1, E Thomas-Tsagli 1
PMCID: PMC2228241  PMID: 9155045

Abstract

p53 and the murine double minute 2 (MDM2) oncoprotein expression was evaluated in paraffin-embedded tissue from 61 patients with central nervous system gliomas (53 astrocytomas and eight oligodendrogliomas) and related to proliferation-associated markers [i.e. proliferating cell nuclear antigen (PCNA), Ki-67 and nuclear organizer regions (NORs)] and epidermal growth factor receptor (EGFR). We used the monoclonal antibodies PC-10, MIB-1, DO-1, 1B1O and EGFR 113 and the colloid silver nitrate (AgNOR) technique. MDM2 and p53 were co-expressed in 28% of cases. A p53-positive/MDM2-negative phenotype was observed in 15% and a p53-negative/MDM2-positive phenotype in 20% of cases. There was a positive correlation of p53 and MDM2 expression with grade and proliferation indices. Univariate analysis in the group of diffuse astrocytomas showed that older age, high histological grade, high PCNA labelling index (LI) and high AgNOR score were associated with reduced overall survival (P < 0.05). p53 LI, Ki-67 LI, AgNOR score, tumour location and grade influenced disease-free survival (P < 0.05), whereas the only parameters affecting post-relapse survival were histological grade and Ki-67 LI (P < 0.1). Multivariate analysis revealed that age, radiotherapy, PCNA LI and p53 LI were the independent predictors of overall survival. p53 LI, Ki-67 LI, MDM2 LI, EGFR LI, grade and type of therapy were independent predictors of disease-free survival, and grade was the only independent predictor of post-relapse survival. Our results indicate that p53 LI and MDM2 LI, EGFR expression as well as proliferation markers (PCNA and Ki-67) are useful indicators of overall and disease-free survival in diffuse astrocytoma patients.

Full text

PDF
1269

Images in this article

1271Figure 1
on p.1271
1271Figure 2
on p.1271
1272Figure 3
on p.1272
1272Figure 4
on p.1272
1273Figure 5
on p.1273
1273Figure 6
on p.1273

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allegranza A., Girlando S., Arrigoni G. L., Veronese S., Mauri F. A., Gambacorta M., Pollo B., Dalla Palma P., Barbareschi M. Proliferating cell nuclear antigen expression in central nervous system neoplasms. Virchows Arch A Pathol Anat Histopathol. 1991;419(5):417–423. doi: 10.1007/BF01605076. [DOI] [PubMed] [Google Scholar]
  2. Barbareschi M., Girlando S., Fellin G., Graffer U., Luciani L., Dalla Palma P. Expression of mdm-2 and p53 protein in transitional cell carcinoma. Urol Res. 1995;22(6):349–352. doi: 10.1007/BF00296873. [DOI] [PubMed] [Google Scholar]
  3. Barbareschi M., Iuzzolino P., Pennella A., Allegranza A., Arrigoni G., Dalla Palma P., Doglioni C. p53 protein expression in central nervous system neoplasms. J Clin Pathol. 1992 Jul;45(7):583–586. doi: 10.1136/jcp.45.7.583. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bigner S. H., Vogelstein B. Cytogenetics and molecular genetics of malignant gliomas and medulloblastoma. Brain Pathol. 1990 Sep;1(1):12–18. doi: 10.1111/j.1750-3639.1990.tb00633.x. [DOI] [PubMed] [Google Scholar]
  5. Cordon-Cardo C., Latres E., Drobnjak M., Oliva M. R., Pollack D., Woodruff J. M., Marechal V., Chen J., Brennan M. F., Levine A. J. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 1994 Feb 1;54(3):794–799. [PubMed] [Google Scholar]
  6. Diedrich U., Lucius J., Baron E., Behnke J., Pabst B., Zoll B. Distribution of epidermal growth factor receptor gene amplification in brain tumours and correlation to prognosis. J Neurol. 1995 Oct;242(10):683–688. doi: 10.1007/BF00866920. [DOI] [PubMed] [Google Scholar]
  7. Figge C., Reifenberger G., Vogeley K. T., Messing M., Roosen N., Wechsler W. Immunohistochemical demonstration of proliferating cell nuclear antigen in glioblastomas: pronounced heterogeneity and lack of prognostic significance. J Cancer Res Clin Oncol. 1992;118(4):289–295. doi: 10.1007/BF01208618. [DOI] [PubMed] [Google Scholar]
  8. Finlay C. A., Hinds P. W., Levine A. J. The p53 proto-oncogene can act as a suppressor of transformation. Cell. 1989 Jun 30;57(7):1083–1093. doi: 10.1016/0092-8674(89)90045-7. [DOI] [PubMed] [Google Scholar]
  9. Haapasalo H., Isola J., Sallinen P., Kalimo H., Helin H., Rantala I. Aberrant p53 expression in astrocytic neoplasms of the brain: association with proliferation. Am J Pathol. 1993 May;142(5):1347–1351. [PMC free article] [PubMed] [Google Scholar]
  10. Hunter T. The epidermal growth factor receptor gene and its product. Nature. 1984 Oct 4;311(5985):414–416. doi: 10.1038/311414a0. [DOI] [PubMed] [Google Scholar]
  11. Iggo R., Gatter K., Bartek J., Lane D., Harris A. L. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet. 1990 Mar 24;335(8691):675–679. doi: 10.1016/0140-6736(90)90801-b. [DOI] [PubMed] [Google Scholar]
  12. Jaros E., Perry R. H., Adam L., Kelly P. J., Crawford P. J., Kalbag R. M., Mendelow A. D., Sengupta R. P., Pearson A. D. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer. 1992 Aug;66(2):373–385. doi: 10.1038/bjc.1992.273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kajiwara K., Nishizaki T., Orita T., Nakayama H., Aoki H., Ito H. Silver colloid staining technique for analysis of glioma malignancy. J Neurosurg. 1990 Jul;73(1):113–117. doi: 10.3171/jns.1990.73.1.0113. [DOI] [PubMed] [Google Scholar]
  14. Karamitopoulou E., Perentes E., Diamantis I., Maraziotis T. Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB 1 monoclonal antibody on archival material. Acta Neuropathol. 1994;87(1):47–54. doi: 10.1007/BF00386253. [DOI] [PubMed] [Google Scholar]
  15. Karamitopoulou E., Perentes E., Melachrinou M., Maraziotis T. Proliferating cell nuclear antigen immunoreactivity in human central nervous system neoplasms. Acta Neuropathol. 1993;85(3):316–322. doi: 10.1007/BF00227728. [DOI] [PubMed] [Google Scholar]
  16. Karkavelas G., Mavropoulou S., Fountzilas G., Christoforidou V., Karavelis A., Foroglou G., Papadimitriou C. Correlation of proliferating cell nuclear antigen assessment, histologic parameters and age with survival in patients with glioblastoma multiforme. Anticancer Res. 1995 Mar-Apr;15(2):531–536. [PubMed] [Google Scholar]
  17. Kleihues P., Burger P. C., Scheithauer B. W. The new WHO classification of brain tumours. Brain Pathol. 1993 Jul;3(3):255–268. doi: 10.1111/j.1750-3639.1993.tb00752.x. [DOI] [PubMed] [Google Scholar]
  18. Korkolopoulou P., Christodoulou P., Lekka-Katsouli I., Kouzelis K., Papanikolaou A., Panayotides I., Mariatos P., Thomas-Tsagli E., Crocker J. Prognostic significance of proliferating cell nuclear antigen (PCNA) expression in gliomas. Histopathology. 1994 Oct;25(4):349–355. doi: 10.1111/j.1365-2559.1994.tb01353.x. [DOI] [PubMed] [Google Scholar]
  19. Korkolopoulou P., Christodoulou P., Papanikolaou A., Thomas-Tsagli E. Proliferating cell nuclear antigen and nucleolar organizer regions in CNS tumors: correlation with histological type and tumor grade. A comparative study of 82 cases on paraffin sections. Am J Surg Pathol. 1993 Sep;17(9):912–919. doi: 10.1097/00000478-199309000-00007. [DOI] [PubMed] [Google Scholar]
  20. Kyritsis A. P., Xu R., Bondy M. L., Levin V. A., Bruner J. M. Correlation of p53 immunoreactivity and sequencing in patients with glioma. Mol Carcinog. 1996 Jan;15(1):1–4. doi: 10.1002/(SICI)1098-2744(199601)15:1<1::AID-MC1>3.0.CO;2-O. [DOI] [PubMed] [Google Scholar]
  21. Lane D. P. Cancer. p53, guardian of the genome. Nature. 1992 Jul 2;358(6381):15–16. doi: 10.1038/358015a0. [DOI] [PubMed] [Google Scholar]
  22. Libermann T. A., Razon N., Bartal A. D., Yarden Y., Schlessinger J., Soreq H. Expression of epidermal growth factor receptors in human brain tumors. Cancer Res. 1984 Feb;44(2):753–760. [PubMed] [Google Scholar]
  23. Louis D. N., Edgerton S., Thor A. D., Hedley-Whyte E. T. Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: a comparative study. Acta Neuropathol. 1991;81(6):675–679. doi: 10.1007/BF00296379. [DOI] [PubMed] [Google Scholar]
  24. Louis D. N. The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol. 1994 Jan;53(1):11–21. doi: 10.1097/00005072-199401000-00002. [DOI] [PubMed] [Google Scholar]
  25. Louis D. N., von Deimling A., Chung R. Y., Rubio M. P., Whaley J. M., Eibl R. H., Ohgaki H., Wiestler O. D., Thor A. D., Seizinger B. R. Comparative study of p53 gene and protein alterations in human astrocytic tumors. J Neuropathol Exp Neurol. 1993 Jan;52(1):31–38. doi: 10.1097/00005072-199301000-00005. [DOI] [PubMed] [Google Scholar]
  26. Maestro R., Dolcetti R., Gasparotto D., Doglioni C., Pelucchi S., Barzan L., Grandi E., Boiocchi M. High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. Oncogene. 1992 Jun;7(6):1159–1166. [PubMed] [Google Scholar]
  27. Maier H., Morimura T., Ofner D., Hallbrucker C., Kitz K., Budka H. Argyrophilic nucleolar organizer region proteins (Ag-NORs) in human brain tumors: relations with grade of malignancy and proliferation indices. Acta Neuropathol. 1990;80(2):156–162. doi: 10.1007/BF00308919. [DOI] [PubMed] [Google Scholar]
  28. Meltzer P. S. MDM2 and p53: a question of balance. J Natl Cancer Inst. 1994 Sep 7;86(17):1265–1266. doi: 10.1093/jnci/86.17.1265. [DOI] [PubMed] [Google Scholar]
  29. Mercer W. E., Shields M. T., Lin D., Appella E., Ullrich S. J. Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):1958–1962. doi: 10.1073/pnas.88.5.1958. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Momand J., Zambetti G. P., Olson D. C., George D., Levine A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992 Jun 26;69(7):1237–1245. doi: 10.1016/0092-8674(92)90644-r. [DOI] [PubMed] [Google Scholar]
  31. Newcomb E. W., Madonia W. J., Pisharody S., Lang F. F., Koslow M., Miller D. C. A correlative study of p53 protein alteration and p53 gene mutation in glioblastoma multiforme. Brain Pathol. 1993 Jul;3(3):229–235. doi: 10.1111/j.1750-3639.1993.tb00749.x. [DOI] [PubMed] [Google Scholar]
  32. Nicoll J. A., Candy E. Nucleolar organizer regions and post-operative survival in glioblastoma multiforme. Neuropathol Appl Neurobiol. 1991 Feb;17(1):17–20. doi: 10.1111/j.1365-2990.1991.tb00689.x. [DOI] [PubMed] [Google Scholar]
  33. Norton A. J., Jordan S., Yeomans P. Brief, high-temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed tissues. J Pathol. 1994 Aug;173(4):371–379. doi: 10.1002/path.1711730413. [DOI] [PubMed] [Google Scholar]
  34. Ohgaki H., Eibl R. H., Wiestler O. D., Yasargil M. G., Newcomb E. W., Kleihues P. p53 mutations in nonastrocytic human brain tumors. Cancer Res. 1991 Nov 15;51(22):6202–6205. [PubMed] [Google Scholar]
  35. Pignatelli M., Stamp G. W., Kafiri G., Lane D., Bodmer W. F. Over-expression of p53 nuclear oncoprotein in colorectal adenomas. Int J Cancer. 1992 Mar 12;50(5):683–688. doi: 10.1002/ijc.2910500503. [DOI] [PubMed] [Google Scholar]
  36. Plate K. H., Rüschoff J., Behnke J., Mennel H. D. Proliferative potential of human brain tumours as assessed by nucleolar organizer regions (AgNORs) and Ki67-immunoreactivity. Acta Neurochir (Wien) 1990;104(3-4):103–109. doi: 10.1007/BF01842827. [DOI] [PubMed] [Google Scholar]
  37. Rasheed B. K., McLendon R. E., Herndon J. E., Friedman H. S., Friedman A. H., Bigner D. D., Bigner S. H. Alterations of the TP53 gene in human gliomas. Cancer Res. 1994 Mar 1;54(5):1324–1330. [PubMed] [Google Scholar]
  38. Reich N. C., Levine A. J. Growth regulation of a cellular tumour antigen, p53, in nontransformed cells. Nature. 1984 Mar 8;308(5955):199–201. doi: 10.1038/308199a0. [DOI] [PubMed] [Google Scholar]
  39. Reifenberger G., Liu L., Ichimura K., Schmidt E. E., Collins V. P. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res. 1993 Jun 15;53(12):2736–2739. [PubMed] [Google Scholar]
  40. Reifenberger G., Prior R., Deckert M., Wechsler W. Epidermal growth factor receptor expression and growth fraction in human tumours of the nervous system. Virchows Arch A Pathol Anat Histopathol. 1989;414(2):147–155. doi: 10.1007/BF00718594. [DOI] [PubMed] [Google Scholar]
  41. Rubio M. P., von Deimling A., Yandell D. W., Wiestler O. D., Gusella J. F., Louis D. N. Accumulation of wild type p53 protein in human astrocytomas. Cancer Res. 1993 Aug 1;53(15):3465–3467. [PubMed] [Google Scholar]
  42. Sallinen P. K., Haapasalo H. K., Visakorpi T., Helén P. T., Rantala I. S., Isola J. J., Helin H. J. Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. J Pathol. 1994 Dec;174(4):275–282. doi: 10.1002/path.1711740407. [DOI] [PubMed] [Google Scholar]
  43. Schröder R., Bien K., Kott R., Meyers I., Vössing R. The relationship between Ki-67 labeling and mitotic index in gliomas and meningiomas: demonstration of the variability of the intermitotic cycle time. Acta Neuropathol. 1991;82(5):389–394. doi: 10.1007/BF00296550. [DOI] [PubMed] [Google Scholar]
  44. Soini Y., Niemelä A., Kamel D., Herva R., Bloigu R., Päkkö P., Vähäkangas K. p53 immunohistochemical positivity as a prognostic marker in intracranial tumours. APMIS. 1994 Oct;102(10):786–792. doi: 10.1111/j.1699-0463.1994.tb05235.x. [DOI] [PubMed] [Google Scholar]
  45. Theunissen P. H., Blaauw G. Proliferating cell nuclear antigen immunostaining and survival in cerebral astrocytoma. Histopathology. 1993 Jul;23(1):75–79. doi: 10.1111/j.1365-2559.1993.tb01186.x. [DOI] [PubMed] [Google Scholar]
  46. Vigliani M. C., Chiò A., Pezzulo T., Soffietti R., Giordana M. T., Schiffer D. Proliferating cell nuclear antigen (PCNA) in low-grade astrocytomas: its prognostic significance. Tumori. 1994 Aug 31;80(4):295–300. doi: 10.1177/030089169408000411. [DOI] [PubMed] [Google Scholar]
  47. Xiao Z. X., Chen J., Levine A. J., Modjtahedi N., Xing J., Sellers W. R., Livingston D. M. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature. 1995 Jun 22;375(6533):694–698. doi: 10.1038/375694a0. [DOI] [PubMed] [Google Scholar]
  48. Zhu A., Shaeffer J., Leslie S., Kolm P., El-Mahdi A. M. Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive irradiation. Int J Radiat Oncol Biol Phys. 1996 Mar 1;34(4):809–815. doi: 10.1016/0360-3016(95)02184-1. [DOI] [PubMed] [Google Scholar]
  49. Zuber P., Hamou M. F., de Tribolet N. Identification of proliferating cells in human gliomas using the monoclonal antibody Ki-67. Neurosurgery. 1988 Feb;22(2):364–368. doi: 10.1227/00006123-198802000-00015. [DOI] [PubMed] [Google Scholar]
  50. van Meyel D. J., Ramsay D. A., Casson A. G., Keeney M., Chambers A. F., Cairncross J. G. p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression. J Natl Cancer Inst. 1994 Jul 6;86(13):1011–1017. doi: 10.1093/jnci/86.13.1011. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES